[Analysis on the proportion of reported hepatitis B cases through pilot surveillance in China during 2006].
OBJECTIVE
To better understand the proportions of reported hepatitis B cases in pilot surveillance cites through investigation and laboratory testing.


METHODS
To confirm the reported cases of hepatitis B by collecting blood specimen and laboratory testing on HBsAg, IgM of Anti-HBc, Anti-HAV in 18 pilot surveillance counties.


RESULTS
Among 2858 cases of hepatitis B reported in 2006, 23.97% of them were reported as suspected acute cases, 14.87% as acute cases, 20.33% as suspected chronic cases, 34.67% as chronic cases, 4.09% as cirrhosis and 2.06% as HCC. Among 1681 reported hepatitis B cases confirmed by laboratory testing, results showed that 24.16% of them were diagnosed as acute hepatitis B, but only 15.37% were confirmed as acute hepatitis B. Although the proportion confirmed as hepatitis B kept consistent as before, misclassification was found.


CONCLUSIONS
In current surveillance system, reported hepatitis B cases were mainly chronic, only up to one third belonged to acute hepatitis B. The reported incidence of hepatitis B did not reflect the real incidence due to misclassification. To better define the burden on hepatitis B disease, it was necessary and urgent to revise the diagnostic criteria and to conduct surveillance on hepatitis B, under separate reporting categories which including acute and chronic cases of the disease.
Cui
Fu-Qiang
FQ
National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Lu
Yong
Y
Wang
Fu-Zhen
FZ
Chen
Yuan-Sheng
YS
Zheng
Hui
H
Zhang
Yong
Y
Gong
Xiao-Hong
XH
Han
Li-Li
LL
Dong
Hong-Jun
HJ
Chen
Chao
C
Ling
Luo-Ya
LY
Zhang
Li
L
Diao
Lin-Qi
LQ
Shao
Xiao-Ping
XP
Fang
Gang
G
Gao
Li
L
Liang
Xiao-Feng
XF
D002681:China / Q000453:epidemiology; D006509:Hepatitis B / Q000175:diagnosis / Q000453:epidemiology*; D006510:Hepatitis B Antibodies / Q000097:blood; D006801:Humans; D015994:Incidence; D010865:Pilot Projects; D011159:Population Surveillance
D006510:Hepatitis B Antibodies